Gliomas Are Driven by Glycolysis: Putative Roles of Hexokinase, Oxidative Phosphorylation and Mitochondrial Ultrastructure
Overview
Affiliations
To elucidate the reasons for glycolytic deviation commonly found in brain tumors, hexokinase (HK) activity, mitochondria-HK binding, oxidative phosphorylation and mitochondrial ultrastructure were studied in 4 human xenografted gliomas. Lactate/pyruvate ratios were increased 3-4 fold and HK activity was of 2-4 fold lower than that of normal rat brain tissue, used as the control. The mitochondria-bound HK (mHK) fraction varied considerably and represented 9 to 69% of the total HK of that normal rat brain. The respiratory activity of glioma mitochondria, assessed by polarography and spectrophotometry, was within the normal range. However, the mitochondrial content of gliomas was lower than in the rat brain tissue, as revealed by the markedly decreased, activities of two unrelated mitochondrial enzymes, cytochrome c oxidase and citrate synthase in glioma homogenates. Electron microscopical studies confirmed the reduced number of mitochondria in 3 out of the 4 gliomas. Profound alterations of mitochondrial ultrastructure, namely of cristae and matrix densities, were observed in the 4 gliomas. The intercrista space was wider in all gliomas and the crista area was larger in 3 out of the 4 gliomas than in normal rat brain. Finally, the outer membrane of glioma mitochondria interacted intimately and extensively with the rough endoplasmic reticulum (RER) and/or nuclear membrane. These results suggest that, because of the very low content of normally functioning mitochondria, gliomas shift their energy metabolism towards a high-level glycolysis to generate their cellular ATP supply, probably through RER-mitochondria interactions and transformation-dependent redistribution of particulate HK from non-mitochondrial to mitochondrial receptors.
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells.
Trejo-Solis C, Castillo-Rodriguez R, Serrano-Garcia N, Silva-Adaya D, Vargas-Cruz S, Chavez-Cortez E Metabolites. 2024; 14(5).
PMID: 38786726 PMC: 11122955. DOI: 10.3390/metabo14050249.
Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: A case report.
Phillips M, Thotathil Z, Hari Dass P, Ziad F, Moon B Oncol Lett. 2024; 27(5):230.
PMID: 38586213 PMC: 10996027. DOI: 10.3892/ol.2024.14363.
Metabolic management of microenvironment acidity in glioblastoma.
Seyfried T, Arismendi-Morillo G, Zuccoli G, Lee D, Duraj T, Elsakka A Front Oncol. 2022; 12:968351.
PMID: 36059707 PMC: 9428719. DOI: 10.3389/fonc.2022.968351.
Seyfried T, Shivane A, Kalamian M, Maroon J, Mukherjee P, Zuccoli G Front Nutr. 2021; 8:682243.
PMID: 34136522 PMC: 8200410. DOI: 10.3389/fnut.2021.682243.
Wenger K, Wagner M, Harter P, Franz K, Bojunga J, Fokas E Cancers (Basel). 2020; 12(12).
PMID: 33261052 PMC: 7760797. DOI: 10.3390/cancers12123549.